naratriptan
Also known as Amerge®, GR-85548A, N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide, N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide, N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide, Naratriptanum, N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
Naratriptan, sold under the brand names Amerge and Naramig among others, is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches. It is a selective serotonin 5-HT1 receptor family agonist.
Chemical data
- Formula
- C17H25N3O2S
- Molecular weight
- 335.5 g/mol
- IUPAC name
- N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
- SMILES
- CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C
- InChIKey
- AMKVXSZCKVJAGH-UHFFFAOYSA-N
- XLogP
- 2
- Polar surface area
- 73.6 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Research
364 papersArticle
10 sectionsContents
- Medical uses
- Efficacy
- Side effects
- Pharmacology
- Mechanism of action
- Chemistry
- History
- Society and culture
- See also
- References
Naratriptan, sold under the brand names Amerge and Naramig among others, is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches. It is a selective serotonin 5-HT1 receptor family agonist.
It was patented in 1987 and approved for medical use in 1997.